aclari inc quick take new strategi valid posit data
aimmun inc quick take appl vs orang palforzia clinic benefit candid
vibrant dementia develop prospect symptomat relev
inc today et sickl cell diseas kol call physician view oxbryta
healthcar inform technolog value-bas reimburs data popul health remain theme
intuit surgic inc anoth qtr growth guid like conserv pt
macrogen inc outlook focu regulatori pipelin execut
manag posit view outlook manag given abat polici uncertainti
click headlin titl taken report summari click titl summari open full pdf report
disclosur section may found page
page
today et sickl cell diseas kol call physician view oxbryta landscap
sickl cell diseas kol call physician view oxbryta landscap
today januari pm et
alethia young head healthcar research senior biotechnolog analyst
presid chief offic foundat sickl cell diseas research
discuss topic call
earli uptak oxbryta sinc approv
physician view oxbryta clinic util scd
discuss near-term long-term uptak oxbryta
thought dynam among oxbryta adakveo p-selectin antibodi novarti nv nc hydroxyurea
post-approv tcd studi impact physician behavior
upcom scd treatment watch
lanetta bront-hal md mph msph presid chief offic foundat sickl cell diseas
research novemb present fscdr independ full servic outpati medic treatment clinic
trial center offer medic care coordin care underserv popul respons strateg
plan scientif administr oversight fscdr dr bront-hal previous associ professor
univers miami school medicin juli august lead nation intern research
popul health scientist field sickl cell diseas rare blood disord community-bas participatori research
chronic diseas manag dr bront-hal extens experi develop program close align
recruit retent underserv underrepres popul treatment sickl cell diseas
breast cancer research clinic trial dr bront-hal receiv md mph msph ba univers
north carolina
head healthcar research
head research sale
disclosur section may found page
head equiti sale trade
head equiti trade
mike cornett us head trade
financials/reit industri
page
outlook focu regulatori pipelin execut
invest summari reiter overweight rate pt yesterday after-hour
compani provid corpor overview updat mostli line expect overal takeaway
flotetuzumab regulatori feedback aml still expect repres key catalyst view
io asset initi result like expect posit read pipelin option
lead asset margetuximab still stori breast gastric cancer thesi
flotetuzumab favor posit refractori aml indic expect posit regulatori updat
year potenti acceler path margetuximab oppti breast cancer like remain limit due competit
headwind frontlin gastric cancer attract expans market pipelin option io asset
provid upsid current estim
flotetuzumab regulatori updat aml major investor focu near term
repres key valu driver beyond view posit fda feedback vs prior potenti
registr studi refractori popul enabl frontrunn evolv space
refractori aml popul base prior kol check refractori aml set like repres clear regulatori
path potenti acceler approv pivot data support
margetuximab combo w/ mahogani phase ii data gastric cancer frontlin still
expect posit ph ii interim result enabl trial expans may lead acceler approv
popul think howev bar potenti acceler approv high modul
chemo-fre regimen mahogani modul could more-compel regimen w/ io agent chemo
yet initi enrol
margetuximab regulatori review on-going breast cancer line potenti adcom pdufa expect
compani expect standard review process timelin result pdufa date
consist street expect also note studi power os popul
specif subgroup fda may seek potenti adcom meet like accord management assess greater
benefit seen f-allel subgroup think margetuximab like receiv regulatori approv breast cancer
line commerci uptak may limit competit headwind
pipelin updat initi data still expect like enoblituzumab
ph ii/iii initi delay head neck cancer major concern view could long-
term driver pipelin option given plan combin agent mahogani modul frontlin
gastric cancer margetuximab also exploratori studi w/ enoblituzumab head neck cancer term
program delay discontinu enoblituzumab phase ii/iii studi w/ agent w/ w/o chemo
frontlin head neck cancer push like around month estim previous
compani gener earli data enoblituzumab w/ current use highli risk-adjust opportun
enoblituzumab po compani also discontinu two earli phase program
 valuat
disclosur section may found page
page
vibrant dementia develop prospect symptomat
invest summari recent host kol call psychiatrist neurologist consid thought
leader alzheim diseas ad space kol made notabl contribut field
particip numer clinic studi investig member independ data monitor committe
week contempl purpos call refresh unpack key takeaway
focu call beyond gener current statu drug develop ad acadia pimavanserin
develop dementia-rel psychosi drp includ psychosi experienc ad patient note
recent preview note two major readout ad space graveyard
fail clinic studi last drug approv believ increas prospect signific paradigm shift
approv two agent within next month paradigm shift may enabl notabl result
harmoni studi pimavanserin drp note well data studi aducanumab
cover young present discuss
result call due dilig includ recent effort renew convict neuro-innov
progress symptomat disease-modifi approach therapi becom increasingli visibl new
year new decad also renew convict breadth mechanisms/target explor
import symptomat therapi irrespect avail drug candid could alter cours
diseas final current coverag believ acadia pima could prove rapidli adopt treat drp
across broad rang dementia patient approv reason enabl label look next
alzheim space reinvigor excit optim resurfac kol note
first meet ad long time saw broad number studi posit late stage earli
stage develop kol mention highlight meet includ acadia pima symptomat
treatment drp addit detail aducanumab data support data target beta amyloid via
gantenerumab show dramat amyloid clearanc sustain time
addit earlier stage program kol found intrigu includ data moderate-to-sever
ad met primari endpoint measur sever impair batteri sib control group treat
donepezil decreas high dose cohort combin donepezil decreas
kol note see compani new target mechan action move forward hepat
growth factor target neuro-inflamm compani like nc even nc
well sever provoc candid involv specif receptor system nmda troriluzol ow
sigma nc candid includ privat compani alzheon az therapi cognit eip
overal view posit signal observ sever studi catalyst increas invest clinic momentum
space result better understand
continu next page
disclosur section may found page
page
anoth qtr growth guid like conserv pt
invest summari reiter overweight rate rais pt follow anoth quarter
strong procedur growth system placement afternoon announc preliminari revenu
beat factset consensu revenu procedur growth y/i beat estim
procedur growth high end guidanc primarili driven growth us
surgeri world-wide urolog procedur introduc full year procedur growth guidanc
fall slightli short consensu midpoint believ procedur growth guidanc like conserv
start year typic adjust procedur growth guidanc throughout year base perform guid
procedur growth time last year ship system global compar
estim driven xi placement rel expect global instal base grew believ
impress revenu procedur volum growth demonstr underli fundament remain strong
maintain long-term posit view stock
revenu well-ahead consensu robust system placement strong asp revenu
significantli beat consensu place system quarter slightli
expect instal base increas slightli lower growth recent quarter
driven trade-in expect system asp record high driven xi vs
placement manag expect system mix fluctuat quarter quarter moder
continu strength procedur volum growth drive instrument revenu beat procedur growth
drove instrument accessori revenu beat procedur growth driven continu strength
us gener surgeri world-wide urolog procedur compani provid addit commentari
specif procedur would expect continu strong growth hernia repair bariatr colorect
acceler chole procedur
initi guidanc appear cautious/conserv issu procedur growth guidanc lower
estim midpoint think like compani revis guidanc upward throughout
year manag continu expect percentag system leas altern financ arrang
increas time trade-in like level short term declin time rais
revenu estim respect also rais ep
estim
valuat pt previous base price-to-earnings previous multipl ep estim
disclosur section may found page
page
invest summari maintain bullish view medic devic suppli sector move
think underli fundament remain strong favor demograph drive procedur volum growth price
pressur seem held check large-cap organ revenu growth like similar
expect consist procedur growth new product launch sustain growth think biggest investor concern
head year valuat large-cap medic devic index trade near high month
ntm price-to-earnings said rel large-cap index trade premium well-below
premium peak decemb expect larger medic devic compani use augment de-risk in-hous
 expect acquisit favor technolog access new market scale highlight ow-rat
top pick
top larg cap rais pt turnaround impress see plenti
runway manag announc reach revenu growth goal six month ahead
schedul impress turnaround reflect stock vs
look see multipl avenu deliv upsid current consensu estim despit see price-to-earnings
multipl almost turn higher point last year still trade discount large-cap med-tech
peer think solid top-lin out-performance close valuat gap zbh four recent knee
launch partial cementless revis rosa total knee drive out-performance see addit
opportun busi line extrem expect benefit syk/wmgi rate
 combin sport med
top mid cap surpris see share pre-announc
close wednesday carri premium valuat investor expect high modest
revenu beat impli ep miss revenu ep guidanc fall short street consensu like
contribut investor disappoint today bullish think guidanc prove
conserv see multipl growth driver drive potenti upsid guidanc includ increas
implant pull-through robot enabl technolog launch increas trauma contribut
acceler intern traction addit expect learn strategi enter robot
hip knee market
top small cap recogn challeng face smaller spine compani think two
small-cap spine name coverag univers pois break-out pre-
announc impress result morn see note multipl catalyst acceler us revenu
coupl modest acceler ou revenu believ top-lin guidanc call
growth similar prove conserv sibn market leadership share quickli expand
market opportun matur market revenu growth gross margin attract signific
amount strateg interest also pre-announc impress result week see note us
spinal implant growth well-abov low single-digit market growth also rais equiti capit
week elimin financ overhang provid addit capit invest new instrument set
upcom product launch remain underappreci asset spine evidenc heavili discount
multipl revenu compar peer like expect deliv top-
line growth guidanc financ overhang remov would expect spne multipl expand
meaning year
disclosur section may found page
page
value-bas reimburs data popul health remain theme
invest summari continu believ sever factor drive increas adopt technolog solut
among healthcar organ driver includ strong feder support value-bas reimburs model
continu payer-provid converg believ vendor robust data analyt popul health solut
best-posit address area inde share perform could impact polit uncertainti
elect year howev believ provid payer continu invest technolog regardless polit
environ believ hospital/health system budget account major spend furthermor servic
drive consum engag enabl improv popul health elimin wast cost remain focu
payer provid specif highlight overweight overweight
 overweight vendor address wide rang issu face healthcar organ
overal view healthcar sector attract posit given increas consumer healthcar said
believ secondari aforement overarch trend
shift value-bas care aliv well overhaul medicar share save program mssp call
pathway success pt acceler account care organ path risk pst
program effect juli take downsid risk vs inde expedit timelin caus
leav mssp program interestingli number live cover contract increas y/i
furthermor value-bas reimburs repres half commerci sector healthcar payment
accord catalyst payment reform addit number elig clinician macra
particip advanc altern payment model apm increas y/i believ vendor
enabl value-bas reimburs well-posit benefit trend
prolifer data enabl popul health manag idc estim healthcar data grow
compound-annual-growth-rate fastest rate among industri mani healthcar organ aim leverag
extens dataset drive effect popul health manag turn organ believ drive
oper effici expens reduct said data come multipl sourc complex
natur view provid popul health data analyt solut pois gain increas
preval use data healthcar junctur believ larg technolog compani
amazon cover alphabet cover competit threat yet howev
probabl furthest along area
top pick inde mani stock healthcar coverag
earnings-driven said believ also opportun higher valuat compani solut
address key industri theme believ offer broad rang solut assist organ move
value-bas reimburs take greater patient financi risk believ uniqu data wareh
analyt capabl enabl provid captur valu popul health data invest
healtheint platform partnership pay dividend near futur view
disclosur section may found page
